Hubbry Logo
Primary immunodeficiencyPrimary immunodeficiencyMain
Open search
Primary immunodeficiency
Community hub
Primary immunodeficiency
logo
7 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
Primary immunodeficiency
Primary immunodeficiency
Primary immunodeficiency
View on Wikipedia
from Wikipedia

Primary immunodeficiencies are disorders in which part of the body's immune system is missing or does not function normally.[1] To be considered a primary immunodeficiency (PID), the immune deficiency must be inborn, not caused by secondary factors such as other disease, drug treatment, or environmental exposure to toxins. Most primary immunodeficiencies are genetic disorders; the majority are diagnosed in children under the age of one, although milder forms may not be recognized until adulthood. While there are over 430 recognized inborn errors of immunity (IEIs) as of 2019, the vast majority of which are PIDs, most are very rare.[2][3][4] About 1 in 500 people in the United States are born with a primary immunodeficiency.[5] Immune deficiencies can result in persistent or recurring infections, auto-inflammatory disorders, tumors, and disorders of various organs. There are currently limited treatments available for these conditions; most are specific to a particular type of PID. Research is currently evaluating the use of stem cell transplants (HSCT) and experimental gene therapies as avenues for treatment in limited subsets of PIDs.

Signs and symptoms

[edit]

The precise symptoms of a primary immunodeficiency depend on the type of defect. Generally, the symptoms and signs that lead to the diagnosis of an immunodeficiency include recurrent or persistent infections or developmental delay as a result of infection. Particular organ problems (e.g. diseases involving the skin, heart, facial development and skeletal system) may be present in certain conditions. Others predispose to autoimmune disease, where the immune system attacks the body's own tissues, or tumours (sometimes specific forms of cancer, such as lymphoma). The nature of the infections, as well as the additional features, may provide clues as to the exact nature of the immune defect.[5]

Causes

[edit]

By definition, primary immune deficiencies are due to genetic causes. They may result from a single genetic defect, but most are multifactorial. They may be caused by recessive or dominant inheritance. Some are latent, and require a certain environmental trigger to become manifest, like the presence in the environment of a reactive allergen. Other problems become apparent due to aging of bodily and cellular maintenance processes.

Diagnosis

[edit]

The basic tests performed when an immunodeficiency is suspected should include a full blood count (including accurate lymphocyte and granulocyte counts) and immunoglobulin levels (the three most important types of antibodies: IgG, IgA and IgM).[6][5]

Other tests are performed depending on the suspected disorder:[5][6]

Due to the rarity of many primary immunodeficiencies, many of the above tests are highly specialised and tend to be performed in research laboratories.[5]

Criteria for diagnosis were agreed in 1999. For instance, an antibody deficiency can be diagnosed in the presence of low immunoglobulins, recurrent infections and failure of the development of antibodies on exposure to antigens. The 1999 criteria also distinguish between "definitive", "probable" and "possible" in the diagnosis of primary immunodeficiency. "Definitive" diagnosis is made when it is likely that in 20 years, the patient has a >98% chance of the same diagnosis being made; this level of diagnosis is achievable with the detection of a genetic mutation or very specific circumstantial abnormalities. "Probable" diagnosis is made when no genetic diagnosis can be made, but the patient has all other characteristics of a particular disease; the chance of the same diagnosis being made 20 years later is estimated to be 85-97%. Finally, a "possible" diagnosis is made when the patient has only some of the characteristics of a disease which are present, but not all.[7]

Classifications

[edit]
Main article: List of primary immunodeficiencies

There are many forms of PID. The International Union of Immunological Societies recognizes nine classes of primary immunodeficiencies, totaling over 120 conditions. A 2014 update of the classification guide added a 9th category and added 30 new gene defects from the prior 2009 version.[8][9] As of 2019, there are approximately 430 forms of PID that have been identified.[4]

Different forms of PID have different mechanisms. Rough categorizations of conditions divide them into humoral immunity disorders, T-cell and B-cell disorders, phagocytic disorders, and complement disorders.[10]

Most forms of PID are very rare. IgA deficiency is an exception, and is present in 1 in 500 people. Some of the more frequently seen forms of PID include common variable immunodeficiency, severe combined immunodeficiency, X-linked agammaglobulinemia, Wiskott–Aldrich syndrome, DiGeorge syndrome and ataxia–telangiectasia.[11]

Treatment

[edit]

The treatment of primary immunodeficiencies depends foremost on the nature of the abnormality. Somatic treatment of primarily genetic defects is in its infancy. Most treatment is therefore passive and palliative, and falls into two modalities: managing infections and boosting the immune system.

Reduction of exposure to pathogens may be recommended, and in many situations prophylactic antibiotics or antivirals may be advised.

In the case of humoral immune deficiency, immunoglobulin replacement therapy in the form of intravenous immunoglobulin (IVIG) or subcutaneous immunoglobulin (SCIG) may be available. Antibiotic prophylaxis is also commonly used to prevent respiratory tract infections in these patients.[12]

In cases of autoimmune disorders, immunosuppression therapies like corticosteroids may be prescribed.

For primary immunodeficiencies that are caused by genetic mutation does not exist a causal therapy that would "repair" the mutation. Although there is a therapeutic option, gene therapy which has been in a trial for few immune deficiencies affecting the hematopoietic system. Over the past two decades there were some successful treatments of patients with specific primary immunodeficiencies (PID), including X-linked severe combined immunodeficiency (SCID), Wiskott–Aldrich syndrome and metabolic conditions such as leukodystrophy.[13]

Gene therapy evolved in the 90s from using of gammaretroviral vectors to more specific self-inactivating vector platforms around 2006.[14] The viral vectors randomly insert their sequences into the genomes. However, it is rarely used because of a risk of developing post-treatment T-cell leukemia as a result of interfering tumor-suppressor genes[14] and because of ethical issues.[15] But the progress in gene therapy is promising for the future of treating primary immunodeficiencies.[11]

Epidemiology

[edit]

A survey of 10,000 American households revealed that the prevalence of diagnosed primary immunodeficiency approaches 1 in 1200. This figure does not take into account people with mild immune system defects who have not received a formal diagnosis.[16]

Milder forms of primary immunodeficiency, such as selective immunoglobulin A deficiency, are fairly common, with random groups of people (such as otherwise healthy blood donors) having a rate of 1:600. Other disorders are distinctly more uncommon, with incidences between 1:100,000 and 1:2,000,000 being reported.[5]

Research

[edit]

Bone marrow transplant may be possible for Severe Combined Immune Deficiency and other severe immunodeficiences.[17]

Virus-specific T-lymphocytes (VST) therapy is used for patients who have received hematopoietic stem cell transplantation that has proven to be unsuccessful. It is a treatment that has been effective in preventing and treating viral infections after HSCT. VST therapy uses active donor T-cells that are isolated from alloreactive T-cells which have proven immunity against one or more viruses. Such donor T-cells often cause acute graft-versus-host disease (GVHD), a subject of ongoing investigation. VSTs have been produced primarily by ex-vivo cultures and by the expansion of T-lymphocytes after stimulation with viral antigens. This is carried out by using donor-derived antigen-presenting cells. These new methods have reduced culture time to 10–12 days by using specific cytokines from adult donors or virus-naive cord blood. This treatment is far quicker and with a substantially higher success rate than the 3–6 months it takes to carry out HSCT on a patient diagnosed with a primary immunodeficiency.[18] T-lymphocyte therapies are still in the experimental stage; few are even in clinical trials, none have been FDA approved, and availability in clinical practice may be years or even a decade or more away.

Induced pluripotent stem cells obtained reprogramming patients' cells, for example leukocytes, are a promising tool to study these pathologies and develop personalized therapies.[19]

History

[edit]

X-linked agammaglobulinemia was one of the first described primary immunodeficiencies, discovered by Ogden Bruton in 1952.[4][20] Primary immunodeficiencies were initially classified in 1970 by a committee of the World Health Organization. At the time, they identified 16 immunodeficiencies. By 1998, the number had reached 50.[21]

Discovery of novel genetic causes of innate immunodeficiencies accelerated greatly in the 2010s due to high-throughput DNA sequencing technologies.[22] As of 2019, more than 430 have been categorized.[4]

See also

[edit]

References

[edit]
[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia

Primary immunodeficiency

View on Grokipedia
from Grokipedia
Primary immunodeficiency, also known as primary immune deficiency or inborn errors of immunity, encompasses more than 550 rare genetic disorders that impair the development or function of the , resulting in heightened vulnerability to infections that are typically mild or easily treatable in healthy individuals, as classified by the International Union of Immunological Societies (IUIS). These conditions are present from birth and arise from genetic mutations that disrupt components of innate or adaptive immunity, such as T cells, B cells, , or complement proteins, rather than external factors like infections or medications. Unlike secondary immunodeficiencies, which develop later due to environmental or acquired causes, primary forms often run in families and may affect males more frequently due to X-linked inheritance patterns. The clinical manifestations of primary immunodeficiency vary widely by type but commonly include recurrent, severe, or opportunistic infections affecting the , , gastrointestinal system, or ears, as well as in infants and autoimmune complications like . Notable examples include severe combined immunodeficiency (SCID), which severely compromises both T- and B-cell function and can be life-threatening without early intervention, and common variable immunodeficiency (CVID), characterized by low antibody levels leading to sinopulmonary infections. Symptoms often emerge in , though some milder forms may not manifest until adulthood, and associated features can include enlarged lymph nodes, , or liver, as well as increased cancer risk. Diagnosis typically begins with recognition of through medical and family history, followed by tests such as immunoglobulin quantification, subset analysis via , response evaluation, and genetic sequencing to identify specific . In the United States, universal for SCID has been implemented in all states since , enabling early detection and improving outcomes for this subset of disorders. Early diagnosis by a clinical immunologist is crucial to prevent irreversible damage from chronic infections or complications like . Management focuses on infection prevention through hygiene practices, vaccinations (when safe), and prophylactic antibiotics, alongside targeted therapies tailored to the underlying defect. Common treatments include intravenous or subcutaneous immunoglobulin replacement (typically 400–600 mg/kg every 3–4 weeks) for antibody deficiencies, enzyme or cytokine replacement for specific metabolic defects, and hematopoietic stem cell transplantation as a potential cure for severe cases like SCID. is an emerging option for certain monogenic forms, such as , though it remains investigational. Lifelong multidisciplinary care is often required, addressing not only physical health but also psychological impacts from chronic illness.

Introduction and Classification

Definition and Overview

Primary immunodeficiency (PI), also known as primary immunodeficiency disorder (PID), refers to a heterogeneous group of more than 550 genetically determined disorders that impair the immune system's ability to protect against infections, malignancies, and other threats. Unlike secondary immunodeficiencies, which arise from external factors such as infections, malnutrition, medications, or environmental exposures, PI stems from inherent genetic defects present from birth. These disorders are rare, affecting approximately 1 in 1,200 individuals in the United States, though underdiagnosis remains a significant issue globally. Most PI disorders are monogenic, resulting from mutations in a single gene, and are inherited in patterns including autosomal recessive (the most common), autosomal dominant, or X-linked. Onset typically occurs in infancy or early childhood, leading to recurrent or severe infections early in life, but some forms manifest later in adolescence or adulthood, contributing to diagnostic delays. PI can disrupt either the adaptive immune system (involving T-cells and B-cells) or the innate immune system (including phagocytes and complement proteins), or both, resulting in combined defects; the severity varies widely from mild recurrent infections to life-threatening conditions. The recognition of PI began in the mid-20th century, with the first description of in 1952 by Ogden Bruton, marking the start of identifying these disorders as distinct from acquired immunodeficiencies. Advances in genomic sequencing technologies since the have accelerated discoveries, expanding the catalog of known genes from fewer than 20 in the to over 550 today, enabling better classification and understanding of their molecular basis.

Types and Classifications

Primary immunodeficiencies, now more comprehensively termed inborn errors of immunity (IEI), are systematically classified by the International Union of Immunological Societies (IUIS) Expert Committee based on the affected immune components and clinical phenotypes. This classification facilitates diagnosis, research, and management by grouping disorders according to immunological, genetic, and syndromic features. The IUIS classification originated in 1999 with an initial report organizing IEI into 10 broad groups reflecting predominant immunological defects, such as antibody deficiencies and combined immunodeficiencies. Over time, advances in genetic sequencing have refined this framework; the 2019 update expanded it into 10 detailed tables covering 430 distinct genetic defects, incorporating emerging phenocopies and oligogenic forms where multiple genes contribute to disease. The 2022 update documented 485 genes underlying diverse phenotypes, including infections, autoimmunity, and autoinflammation. As of the 2024 update, the classification recognizes 559 IEI associated with 508 genes and 4 copy number variations, adding 67 novel monogenic defects and 2 phenocopies since 2022. Recent genomic discoveries, such as hypomorphic variants in JAK3 identified through next-generation sequencing, have expanded recognition of atypical presentations like Omenn syndrome within severe combined immunodeficiency (SCID). The current IUIS framework divides IEI into 10 tables, emphasizing the primary immunological pathway disrupted while noting overlaps, such as autoinflammatory conditions resembling immune dysregulation. Below are the major categories with representative examples:
  • Combined Immunodeficiencies (Table I): These affect both T- and B-cell development and function, often presenting as SCID with profound susceptibility to infections. Subtypes include X-linked SCID caused by mutations in IL2RG (encoding the common gamma chain of receptors, leading to absent T and NK cells with present but nonfunctional B cells) and autosomal recessive ADA-SCID due to ADA mutations (resulting in toxic purine accumulation that impairs lymphocyte survival and function). Recent additions include PSMB10 defects causing Omenn-like SCID with abnormal T-cell expansion.
  • Syndromic Combined Immunodeficiencies (Table II): Combined defects accompanied by non-immune features, such as developmental anomalies. Examples include (chromosomal 22q11.2 deletion affecting TBX1, causing thymic hypoplasia, conotruncal heart defects, and ) and Wiskott-Aldrich syndrome (WAS mutations leading to , eczema, and recurrent infections due to cytoskeletal defects in hematopoietic cells). Very early-onset (VODI) variants, like those in TTC7A, fall here with combined and intestinal .
  • Predominantly Antibody (Humoral) Deficiencies (Table III): Disorders primarily impairing B-cell differentiation or antibody production, resulting in recurrent sinopulmonary infections. Key examples are (BTK mutations blocking B-cell maturation, causing near-absent circulating B cells and immunoglobulins) and hyper-IgM syndrome (e.g., CD40LG defects disrupting T-B cell interactions, leading to elevated IgM with low IgG/A/E). Newer entries include PAX5 mutations associated with agammaglobulinemia.
  • Diseases of Immune Dysregulation (Table IV): Defects causing uncontrolled immune activation, manifesting as or lymphoproliferation. Examples encompass IPEX syndrome (FOXP3 mutations impairing regulatory T cells, leading to multiorgan ) and (ALPS, FAS pathway defects causing defective and lymphadenopathy).
  • Congenital Defects of Phagocyte Number or Function (Table V): Impairments in or activity, predisposing to bacterial and fungal infections. (CGD), due to mutations in components like CYBB (X-linked) or NCF1 (autosomal), exemplifies this with defective reactive oxygen production leading to formation.
  • Defects in Intrinsic and Innate Immunity (Table VI): Disruptions in or signaling pathways, often causing narrow susceptibility to specific pathogens. (TLR) deficiencies, such as TLR3 mutations increasing risk, highlight this category.
  • Autoinflammatory Disorders (Table VII): Primarily innate immune overactivation without adaptive defects, featuring recurrent fevers and inflammation. (FMF; mutations activating IL-1β pathway) overlaps with immune dysregulation but is classified here for its episodic .
  • Complement Deficiencies (Table VIII): Impairments in the complement cascade, increasing meningococcal infection risk. C3 deficiency (C3 mutations) exemplifies early classical/alternative pathway defects leading to systemic lupus erythematosus-like autoimmunity.
  • Bone Marrow Failure Syndromes (Table IX): Hematopoietic stem cell defects with secondary immunodeficiency. (e.g., FANCA mutations causing defects, , and cancer predisposition) is a representative example.
  • Phenocopies of Inborn Errors of Immunity (Table X): Acquired or somatic mimics of monogenic IEI, such as autoantibodies against IL-27 causing recurrent infections or somatic JAK1 gain-of-function variants leading to immune dysregulation. These are included to distinguish from defects while noting similar phenotypes.
This structure accommodates the growing recognition of oligogenic inheritance and phenocopies, ensuring the classification remains dynamic as new genes are identified.

Etiology and Pathophysiology

Genetic Causes

Primary immunodeficiencies (PIDs) arise predominantly from monogenic mutations, with autosomal recessive (AR) inheritance being the most common pattern, accounting for approximately 68-70% of known PID-associated genes. X-linked inheritance represents about 6% of genes but contributes to roughly 20% of cases in males due to its impact on hemizygous individuals, while patterns occur in around 21% of genes, often involving gain-of-function or dominant-negative effects. De novo mutations, digenic inheritance (involving two genes), and polygenic forms are rarer, comprising less than 5% of cases, though they can complicate diagnosis in sporadic presentations. Exemplary genes illustrate these patterns: mutations in IL2RG cause X-linked severe combined immunodeficiency (SCID) by disrupting cytokine signaling essential for lymphocyte development. Similarly, BTK mutations underlie X-linked agammaglobulinemia, impairing B-cell maturation and antibody production, while CYBB defects lead to X-linked chronic granulomatous disease (CGD), affecting phagocyte oxidative burst. In contrast, AR SCID often results from ADA mutations, which cause toxic metabolite accumulation and lymphocyte apoptosis. Recent advances, including whole-genome sequencing, have identified novel variants in the NF-κB pathway, such as heterozygous NFKB1 splice-site mutations presenting as common variable immunodeficiency and NFKB2 gain-of-function alleles linked to autoantibody production, reported between 2023 and 2025. Genetic heterogeneity within PIDs is pronounced, with allelic variations in the same gene producing diverse phenotypes; for instance, hypomorphic mutations—those retaining —often result in milder or atypical disease compared to null alleles. Examples include hypomorphic RAG1 variants causing partial T- and B-cell defects rather than full SCID, and similar IL2RG mutations leading to less severe combined immunodeficiencies. This variability underscores the spectrum from complete loss-of-function to leaky phenotypes, influencing clinical severity and age of onset. Consanguinity significantly elevates PID risk, particularly for AR forms, with meta-analyses showing odds ratios up to 2.6 times higher in offspring of consanguineous parents compared to non-consanguineous controls. In regions with high rates of cousin marriages, such as parts of the , AR PIDs constitute 40-50% of cases, far exceeding global averages, due to increased homozygosity of recessive alleles.

Molecular Mechanisms

Primary immunodeficiencies (PIDs) arise from genetic defects that disrupt critical cellular and biochemical pathways in the immune system, leading to impaired host defense, autoimmunity, or lymphoproliferation. These molecular disruptions primarily affect adaptive and innate immune components, where mutations in key genes halt development, signaling, or effector functions of immune cells. For instance, in B-cell maturation, defects in Bruton's tyrosine kinase (BTK) signaling prevent pre-B cell expansion and differentiation in the bone marrow, resulting in a near-complete absence of mature B cells and immunoglobulins, as seen in X-linked agammaglobulinemia. Similarly, in T-cell development, mutations in recombination-activating genes 1 and 2 (RAG1/RAG2) impair V(D)J recombination, arresting lymphocyte maturation at early stages and causing severe combined immunodeficiency (SCID) with profound T- and B-cell lymphopenia. Innate immune pathways are equally vulnerable, with phagocyte defects exemplifying oxidative burst failure. (CGD) stems from mutations in genes encoding the complex (e.g., CYBB, NCF1), which assembles in phagocyte membranes to generate radicals during respiratory bursts; this deficiency leaves microbes unopposed, leading to granuloma formation and recurrent infections. Complement activation cascades, involving classical, alternative, and lectin pathways converging on C3 and the membrane attack complex, are disrupted in deficiencies of components like C1q, C2, or C3, impairing opsonization, , and of pathogens and predisposing to encapsulated bacterial infections such as . Beyond these, specific mechanisms include dysregulation in (ALPS), where mutations block Fas-mediated death signaling in activated lymphocytes, causing double-negative T-cell accumulation and autoimmunity. Cytokine signaling blocks, such as in autosomal dominant hyper-IgE syndrome due to dominant-negative variants, disrupt IL-6, IL-10, and IL-21 pathways, impairing Th17 differentiation and mucosal immunity while elevating IgE. Innate viral sensing fails in IRF7 deficiency, where impaired type I production via TLR and RIG-I pathways heightens susceptibility to and other RNA viruses. Epigenetic and post-transcriptional modifiers contribute to PID phenotypes. Epigenetic alterations, including and histone modifications, can exacerbate genetic defects by silencing immune genes or altering accessibility in affected cells, as observed in regulatory T-cell dysfunction in certain PIDs. Non-coding RNAs, such as microRNAs and long non-coding RNAs, modulate PID severity by targeting mRNA stability and translation in immune pathways. Whole-genome sequencing has revealed mosaic mutations—somatic variants in hematopoietic progenitors—as causes of atypical or late-onset PIDs, explaining variable expressivity in conditions like Wiskott-Aldrich syndrome or STAT3-related disorders. These molecular defects often interplay to promote autoimmunity or malignancy. In combined immunodeficiencies involving DNA repair genes like ATM, impaired double-strand break repair during V(D)J recombination and class-switch recombination leads to genomic instability, fostering autoreactive lymphocyte survival and oncogenic transformations, as evidenced by increased lymphoma risk in ataxia-telangiectasia. Such mechanisms underscore how PID disruptions extend beyond infection susceptibility to dysregulated immune homeostasis.

Clinical Presentation

Signs and Symptoms

Primary immunodeficiencies (PIDs) often present with recurrent, severe, or unusual infections that fail to respond adequately to standard treatments, reflecting defects in specific immune components. Patients with antibody deficiencies, such as (CVID), commonly experience recurrent sinopulmonary infections, including , , and caused by encapsulated bacteria like and . In contrast, T-cell defects, including (SCID), predispose to severe viral infections such as (CMV) and opportunistic pathogens like , often manifesting in early infancy with life-threatening or disseminated disease. Fungal infections, such as or , are prominent in innate immunity disorders like (CGD), where catalase-positive organisms lead to abscesses in lungs, skin, or liver. Non-infectious manifestations frequently accompany infectious symptoms and can provide early clues to PID. Failure to thrive and chronic diarrhea are common in SCID and other combined immunodeficiencies, often due to persistent gastrointestinal infections or malabsorption. Eczema and granulomatous inflammation occur in disorders like hyper-IgE syndrome or CGD, while autoimmune features, such as cytopenias or (IBD)-like enteropathy, emerge in conditions including (ALPS) or XIAP deficiency. Age-specific presentations include neonatal omphalitis in leukocyte adhesion deficiencies and later-onset autoimmunity in adulthood for many PIDs. Organ-specific involvement varies by PID type but often leads to chronic damage if unrecognized. Respiratory complications, such as from recurrent pneumonias, are typical in humoral immunodeficiencies like CVID. Gastrointestinal symptoms, including chronic and IBD-like colitis, are prevalent in XIAP deficiency or CVID, affecting up to 40% of patients with infectious or inflammatory enteropathy. Skin manifestations range from persistent and eczema in deficiency to recurrent abscesses in CGD or hyper-IgE syndrome. The clinical presentation of PIDs shows significant variability, with some individuals remaining asymptomatic carriers, such as in selective IgA deficiency, while others experience late-onset disease in adulthood, as seen in CVID where diagnosis often occurs after years of symptoms. This heterogeneity underscores the importance of considering PID in patients with atypical infection patterns or non-infectious inflammatory signs across all age groups.

Complications

Primary immunodeficiencies (PIDs) predispose individuals to a range of long-term complications due to chronic immune dysregulation and recurrent infections, leading to progressive organ involvement and increased morbidity if not managed early. These secondary effects often emerge over time and can significantly impact , with autoimmune phenomena, malignancies, and structural organ damage being prominent. Autoimmune diseases occur frequently in PIDs, with an overall prevalence of approximately 26% across various disorders, reflecting failed mechanisms. In (CVID), autoimmune manifestations affect 20-30% of patients, including cytopenias such as immune thrombocytopenia and . (ALPS) is particularly associated with cytopenias, which can be severe and recurrent, often requiring immunosuppressive therapy. Selective IgA deficiency carries a 5-30% risk of autoimmunity, with (e.g., Hashimoto's or ) being a common example, contributing to endocrine dysfunction. In hyper-IgM syndromes, autoimmune complications arise in 10-21% of cases, underscoring the heightened susceptibility in antibody deficiency states. Malignancies represent a significant long-term risk in PIDs, with a cumulative incidence of 4-25% by age 50, driven by impaired immune surveillance and genetic instability. Hematologic cancers, particularly lymphomas, predominate, showing a 10-fold increased risk in affected males and an 8-fold risk in females compared to the general population. In Wiskott-Aldrich syndrome, lymphomas occur at notably high rates, often as , due to cytoskeletal defects promoting lymphoproliferation. Solid tumors, such as gastric carcinoma or , are less common but reported in syndromes like ataxia-telangiectasia, with no overall elevation in common epithelial cancers like lung or breast tumors. The risk escalates with prolonged survival post-diagnosis, highlighting the need for vigilant oncologic screening. Chronic infections and inflammation in PIDs frequently result in organ damage, manifesting as structural and functional impairments. , a hallmark pulmonary complication, affects up to 33% of PID patients, characterized by irreversible airway dilation and leading to recurrent exacerbations and reduced lung function over time. Liver disease complicates at least 10% of CVID cases, often presenting as nodular regenerative hyperplasia, , or granulomatous infiltration, which can progress to and . Growth retardation is observed in multiple PIDs, such as , due to nutritional deficits from and chronic illness, impacting up to 47% of pediatric cases. Infertility may arise in syndromic PIDs through direct gonadal involvement or secondary effects of chronic disease, though it is not uniformly affected across all disorders. Other complications include and neurological deficits, which arise from persistent inflammatory states or metabolic toxicities. , a rare but life-threatening of chronic infections, occurs in various PIDs like immunoglobulin deficiencies and , with renal involvement in 80% of cases and a mean diagnostic delay of 16 years from PID onset. In adenosine deaminase-deficient (ADA-SCID), untreated accumulation of toxic metabolites leads to neurological issues, including , learning disabilities, fine motor impairments, and , which can be mitigated by early intervention.

Diagnosis and Screening

Diagnostic Approaches

Diagnosis of primary immunodeficiencies typically begins with initial laboratory evaluations to identify abnormalities suggestive of immune dysfunction. A (CBC) with differential is a fundamental test, revealing lymphopenia, , or other cytopenias that may indicate specific defects, such as (SCID) or (CGD). Serum immunoglobulin levels, including IgG, IgA, IgM, and IgE, are measured to detect or selective deficiencies, which are hallmarks of antibody production disorders like (CVID). Assessment of vaccine responses, such as antibody titers to or pneumococcal antigens, evaluates functional production and helps confirm impairments. Advanced diagnostic assays provide more precise characterization of immune cell populations and functions. is essential for quantifying lymphocyte subsets, including + and CD8+ T cells, B cells (via or markers), and natural killer cells, aiding in the identification of disorders like SCID or . Functional tests assess cellular activity; for instance, the nitroblue tetrazolium (NBT) test or dihydrorhodamine (DHR) evaluates oxidative burst in to diagnose CGD. Genetic sequencing, including next-generation sequencing (NGS) panels or whole-exome sequencing (WES), identifies causative mutations in over 400 known genes associated with primary immunodeficiencies, confirming molecular diagnoses. Established criteria guide the interpretation of clinical and laboratory findings to establish a probable . The International Union of Immunological Societies (IUIS) provides phenotypic classification systems that orient based on clinical features, immunological profiles, and genetic data, encompassing 559 distinct defects grouped into 10 categories. The Jeffrey Modell Foundation (JMF) criteria, including 10 warning signs such as recurrent infections requiring intravenous antibiotics or , support probable primary immunodeficiency when combined with laboratory abnormalities, prompting further evaluation. Tissue biopsies, such as those of granulomas in CGD or lymph nodes to assess architecture in combined immunodeficiencies, offer histopathological confirmation of immune dysregulation. Diagnostic challenges arise from mimics, including secondary immunodeficiencies due to infections like , malignancies, or medications, which necessitate exclusion through targeted testing. A multidisciplinary approach involving clinical immunologists, geneticists, and pathologists is crucial to integrate findings, avoid misdiagnosis, and expedite confirmatory testing in complex cases.

Newborn Screening

Newborn screening programs for primary immunodeficiencies (PIDs), particularly (SCID), utilize assays to detect markers of immune cell development in dried blood spots collected shortly after birth. The primary method involves quantitative (qPCR) to measure excision circles (TRECs) and kappa-deleting recombination excision circles (KRECs), which are byproducts of T- and B-cell receptor gene rearrangement during maturation. TRECs indicate recent thymic emigrants and are markedly reduced or absent in SCID due to impaired T-cell production, while KRECs similarly reflect B-cell deficits in certain PIDs. These assays achieve high sensitivity for typical SCID, exceeding 95%, with many studies reporting 100% detection rates for classic cases when samples are obtained at birth. As of 2025, SCID newborn screening has been universally implemented across all 50 U.S. states since 2018, screening millions of infants annually. In , adoption varies by country, with at least 20 nations including programs that screen between 4,500 and over 1 million newborns each year, though not yet uniform across the entire ; recent expansions include , which started in April 2025, and ongoing pilots in others like the . Globally, approximately 26 countries conduct SCID screening, with efforts extending to other PIDs such as (CGD) through exploratory assays for neutrophil function or genetic markers, though these remain in early research phases. In , data from 2019–2021 indicate that newborn screening identified 32% of SCID cases at a median age of 9 days, compared to 9 months for clinically diagnosed cases. False-positive results, where TREC or KREC levels fall below cutoffs without SCID, occur in about 0.1–0.3% of screened infants and are often linked to non-SCID conditions such as prematurity, which reduces thymic output and TREC copies, or congenital anomalies like cardiac defects. These necessitate confirmatory testing to avoid unnecessary anxiety, with repeat sampling recommended for preterm infants. False negatives are rarer for typical SCID but can occur in hypomorphic variants or late-onset forms, where residual T-cell production yields TREC levels above the threshold at birth, potentially delaying until infections manifest. The implementation of these screening programs has significantly improved outcomes, with population-based studies showing five-year overall survival after hematopoietic cell transplantation rising from 73% in clinically diagnosed SCID to 92% in those identified via , primarily due to pre-infection intervention. This reduction in early mortality, from approximately 27% to 8%, underscores the program's life-saving potential. Economic analyses further support cost-effectiveness, estimating incremental costs of $30,000–$35,000 per life-year saved, rendering universal screening a high-value across diverse healthcare systems.

Management and Treatment

Therapeutic Options

Immunoglobulin replacement therapy is a cornerstone treatment for primary antibody deficiencies, such as common variable immunodeficiency (CVID) and X-linked agammaglobulinemia, where patients exhibit impaired production of antibodies. Intravenous immunoglobulin (IVIG) or subcutaneous immunoglobulin (SCIG) is administered at a typical dose of 400-600 mg/kg per month, adjusted based on clinical response and trough IgG levels to maintain protective immunity. This therapy has been shown to reduce the frequency and severity of bacterial infections by approximately 50-70%, significantly improving quality of life and preventing chronic lung damage. Hematopoietic stem cell transplantation (HSCT) offers a curative option for severe primary immunodeficiencies, including (SCID) and (CGD). In SCID, HSCT restores functional immune cells, achieving overall rates exceeding 90% when using matched unrelated donors and appropriate conditioning regimens, such as myeloablative to prevent graft rejection. For CGD, HSCT success rates are similarly high, around 85-95% with matched donors, reducing the risk of life-threatening infections and inflammatory complications through engraftment of donor . Conditioning regimens are tailored to the patient's age and condition to minimize toxicity while ensuring durable engraftment. Enzyme replacement therapy with polyethylene glycol-conjugated adenosine deaminase (PEG-ADA) is indicated for adenosine deaminase-deficient SCID (ADA-SCID), providing exogenous enzyme to detoxify toxic metabolites and support immune reconstitution. PEG-ADA dosing starts at 30 units/kg weekly, escalating as needed, and has demonstrated sustained immune improvement in over 80% of patients, though it is not curative and requires lifelong administration. Gene therapy represents an advancing curative approach; Strimvelis, an autologous hematopoietic stem cell gene therapy, was approved in 2016 for ADA-SCID and achieves immune recovery in approximately 80% of treated patients with a single administration. By 2025, additional gene therapies for other PIDs, such as the lentiviral-based Waskyra for Wiskott-Aldrich syndrome, have gained regulatory approval in Europe (positive CHMP opinion on November 14, 2025) and are under FDA review, offering >70% success in restoring gene function without donor matching. Targeted therapies address specific molecular defects in certain primary immunodeficiencies. Janus kinase (JAK) inhibitors, such as ruxolitinib or tofacitinib, are used off-label for STAT3 gain-of-function mutations, which cause autoinflammatory and autoimmune phenotypes; these agents block hyperactive signaling, leading to partial or complete clinical improvement in approximately 90% of cases with reduced autoimmunity and infections. Antibiotic prophylaxis, particularly with trimethoprim-sulfamethoxazole (TMP-SMX) at 5 mg/kg trimethoprim three times weekly, is recommended for T-cell deficiencies to prevent Pneumocystis jirovecii pneumonia, reducing incidence by over 90% in at-risk patients.

Supportive Care

Supportive care in primary immunodeficiencies (PIDs) encompasses a range of non-curative interventions aimed at preventing infections, addressing nutritional deficiencies, supporting well-being, and providing comfort in severe cases to enhance . These strategies are essential adjuncts to primary therapies, focusing on mitigating the impact of recurrent infections and chronic complications while promoting overall patient stability. Guidelines from organizations such as the Immune Deficiency Foundation emphasize individualized plans that consider the specific PID subtype and patient age. Infection prophylaxis plays a central role in reducing morbidity from recurrent bacterial, viral, and fungal infections common in PIDs. Non-live vaccines, such as those for pneumococcus (PCV13 and PPSV23), type b (Hib), and meningococcus, are recommended for all PID patients to bolster immunity against encapsulated , though responses may be suboptimal in severe cases. Live vaccines, including measles-mumps-rubella (MMR), varicella, oral polio, and , are contraindicated in patients with severe T- or B-cell deficiencies (e.g., [SCID] or ) due to the risk of disseminated from attenuated pathogens; this applies particularly during periods of active or immunoglobulin replacement therapy. Antimicrobial prophylaxis is widely employed, with trimethoprim-sulfamethoxazole (TMP-SMX) used daily or thrice weekly to prevent bacterial infections and pneumonia in susceptible patients, such as those with hyper-IgM syndrome. In (CGD), itraconazole serves as prophylaxis for fungal infections. For humoral immunodeficiencies like (CVID), azithromycin or amoxicillin is initiated if infections persist despite immunoglobulin therapy, with dosing adjusted to minimize antibiotic resistance. Nutritional and growth support addresses and , which affect up to one-third of PID patients due to chronic gastrointestinal involvement, such as enteropathy in CVID or . Enteral feeding via nasogastric or tubes is recommended for children with persistent , , or inability to meet caloric needs orally, improving weight and z-scores in conditions like SCID or post-hematopoietic stem cell transplantation. A balanced diet with monitoring during acute illnesses is standard, but supplements should be used cautiously due to limited evidence for immune-boosting claims and potential interactions. Bone health monitoring is crucial, as and occur earlier in PID patients, particularly older women or those on corticosteroids for autoimmune complications; (DEXA) screening is advised at a younger age than general population guidelines, with interventions like exercise and calcium/ supplementation to mitigate risks from chronic or immobility. Psychosocial aspects of care involve comprehensive family counseling to manage the emotional burden of chronic illness, including anxiety, isolation, and family stress, with genetic counseling recommended post-diagnosis to discuss inheritance risks and reproductive options. Patient registries like the United States Immunodeficiency Network (USIDNET) facilitate research while providing data-driven support, enabling access to clinical trials and peer networks for affected families. Education on avoidance of exposures is integral, advising patients to minimize contact with crowds, ill individuals, and environmental pathogens (e.g., through hand hygiene, masks during outbreaks, and avoiding unpasteurized foods), which helps reduce infection frequency without overly restricting daily activities. For severe, untreatable PIDs such as advanced SCID or multisystem complications unresponsive to curative interventions, palliative approaches prioritize symptom relief, , and end-of-life planning to maintain dignity and family involvement. These include multidisciplinary teams addressing , respiratory distress, and nutritional comfort, integrated early to align with and family goals.

Epidemiology and History

Prevalence and Distribution

Primary immunodeficiencies (PIDs), also referred to as inborn errors of immunity (IEIs), affect approximately 1 in 1,200 live births in high-resource settings such as the , excluding more common conditions like selective IgA deficiency. Specific subtypes exhibit varying incidences: (SCID) occurs in about 1 in 50,000 to 58,000 live births, while (CVID) has a prevalence of roughly 1 in 25,000 to 50,000 individuals worldwide. These estimates reflect improved detection through and registries, though true global incidence may be higher due to underreporting. In regions with high rates, such as the where consanguineous marriages occur in 20-50% of unions, PID is substantially elevated owing to the predominance of autosomal recessive forms. Estimates in these areas suggest higher incidence due to consanguinity, with reported up to approximately 1 in 3,000 live births in some studies, compared to lower rates in non-consanguineous populations, highlighting the genetic influence on disease distribution. Geographic disparities are pronounced, with significant underdiagnosis in low-resource settings across , , and due to limited access to diagnostic tools and specialized services. Reported rates in these areas are often 10- to 100-fold lower than in or , despite comparable or higher underlying incidence influenced by and environmental factors. The International Union of Immunological Societies (IUIS) classifications, updated through 2024, incorporate increasing contributions from diverse global registries, aiding better epidemiological mapping in underrepresented regions. Approximately 80% of PID cases manifest in childhood, with the remainder diagnosed in adulthood as awareness grows and milder forms are recognized later in life. Overall, males comprise about 58% of diagnosed cases globally, driven by X-linked disorders; for instance, up to 85% of SCID cases without specified etiology are male, reflecting the prevalence of X-linked variants like those in IL2RG. Detection rates have risen steadily with the expansion of programs, particularly for SCID using excision circle (TREC) assays, leading to earlier interventions. This has contributed to declining mortality; in screened SCID populations, 5-year survival post-hematopoietic stem cell transplantation reaches 92.5%, a marked improvement from pre-screening era rates of around 74%.

Historical Development

The recognition of primary immunodeficiencies (PIDs) as distinct clinical entities emerged in the mid-20th century, driven by observations of children with severe, recurrent infections due to underlying immune defects. In 1952, Ogden C. Bruton reported the first documented case of (also known as Bruton's agammaglobulinemia), describing a with profound and absent B cells who suffered repeated bacterial infections; this marked the inaugural identification of an inherited antibody deficiency syndrome. Complementing this, in 1958, Walter H. Hitzig and colleagues described Swiss-type agammaglobulinemia, the initial characterization of (SCID), a life-threatening condition involving combined T- and B-cell deficiencies leading to profound susceptibility to infections; this report distinguished SCID from isolated antibody defects like Bruton's disease. The 1970s brought systematic classification efforts, with a 1970 World Health Organization (WHO) committee establishing a uniform nomenclature for the then-known 16 PIDs, facilitating clinical recognition and research. Molecular insights accelerated in the 1980s and 1990s, exemplified by the 1993 identification of mutations in the BTK gene as the cause of , which illuminated B-cell signaling pathways and paved the way for genetic diagnosis. That decade culminated in the International Union of Immunological Societies (IUIS) issuing its inaugural expert committee report in 1999, classifying 70 PID diseases linked to defects in 40 genes and providing a framework for phenotypical and molecular categorization. The 2000s ushered in the genomic era, bolstered by the Human Genome Project, which enabled comprehensive curation of PID-associated genes under standardized nomenclature from the Human Genome Organisation (HUGO), accelerating the identification of over 100 novel defects by mid-decade. Practical advances included the 2008 pilot rollout of newborn screening for SCID in Wisconsin, using T-cell receptor excision circle (TREC) assays to detect cases early and improve survival rates nationwide. IUIS classifications expanded rapidly thereafter, reaching 430 genes by the 2019 update, which incorporated phenotypic diversity across immune components. The 2022 IUIS revision further documented 485 genes, and the 2024 update (published January 2025) added 63 novel IEIs, bringing the total to 555. Post-2020, the COVID-19 pandemic highlighted vulnerabilities in PID cohorts, with clinical reports noting increased autoimmunity manifestations, such as novel autoimmune cytopenias, potentially triggered by SARS-CoV-2 in immunodeficient individuals.

Current Research and Future Directions

Ongoing Studies

Active clinical trials registered on are investigating optimizations in (HSCT) for primary immunodeficiencies, particularly through reduced-intensity conditioning (RIC) regimens to minimize toxicity while maintaining efficacy. For instance, the Two Step Haplo With Radiation Conditioning trial (NCT05031897) evaluates a lower-intensity approach prior to HSCT to reduce transplant-related mortality in patients with inborn errors of immunity. Similarly, the Allogeneic Transplant for Patients With Inborn Errors of Immunity trial (NCT04339777) assesses fludarabine-based low-intensity conditioning in and related disorders, with ongoing enrollment as of 2025. The Primary Immune Deficiency Treatment Consortium (PIDTC) is conducting longitudinal studies on long-term outcomes following HSCT and other interventions for primary immunodeficiencies. A 2023 PIDTC landmark study analyzed posttransplantation complications in patients, revealing increasing late effects over time, such as and malignancies, based on data from 399 cases across 32 centers. Updated analyses through 2025, including a 36-year summary report of 902 children, continue to track event-free survival and overall survival improvements, emphasizing the role of in enhancing outcomes. European cohort studies via the European Society for Immunodeficiencies (ESID) registry are monitoring over 30,000 patients with inborn errors of immunity, with a 2023-2025 emphasis on post-HSCT complications such as and infections. The ESID registry's 1994-2024 report details treatment outcomes, including HSCT success rates exceeding 80% in well-characterized cohorts, while highlighting regional variations in access to care. In , the Latin American Society for Immunodeficiencies (LASID) registry tracks approximately 9,300 patients, focusing on diagnostic delays and post-HSCT management in resource-limited settings, with recent data from 2024 underscoring the need for improved complication surveillance. Biomarker research is advancing early detection through standardized flow cytometry panels that assess lymphocyte subsets and functional defects in suspected primary immunodeficiency cases. A 2024 multicenter study validated -based assays for rapid diagnosis of inborn errors of immunity prior to genetic confirmation. Concurrently, applications are improving genetic variant interpretation by integrating genomic data with clinical phenotypes; a 2025 review in the Journal of Allergy and Clinical Immunology outlines AI models that enhance variant pathogenicity classification, reducing diagnostic turnaround from months to days in cohort analyses. Ongoing vaccination studies are evaluating the and immunogenicity of mRNA-based vaccines in primary immunodeficiency patients, with post-2023 data indicating variable responses depending on the underlying defect. A 2025 reported that while mRNA vaccines were generally safe with low rates of severe adverse events, humoral responses waned variably within six months in inborn errors of immunity cases, necessitating booster strategies. Long-term assessments through 2025 confirm no increased risk of or infections attributable to in this population.

Emerging Therapies

Gene editing technologies, particularly CRISPR-Cas9, represent a promising frontier for treating primary immunodeficiencies (PIDs) by precisely correcting genetic mutations. In approaches, hematopoietic stem cells (HSCs) are harvested, edited using CRISPR-Cas9 to disrupt faulty genes or insert functional ones, and reinfused following conditioning, akin to (HSCT). This method has shown efficacy in overlapping conditions like beta-thalassemia, where CRISPR-Cas9 editing of the BCL11A gene in HSCs induced production, achieving transfusion independence in early trials; similar strategies are being adapted for PIDs such as adenosine deaminase-deficient (ADA-SCID) to restore function without viral vectors, with 2025 progress in trials for WHIM syndrome. For gene editing, lipid nanoparticle delivery of CRISPR-Cas9 targets liver-produced complement proteins in defects like C3 or deficiencies, enabling direct correction without cell extraction; preclinical models have demonstrated up to 40% editing efficiency in hepatocytes, restoring complement activity and reducing inflammatory cascades. Cellular therapies are advancing to address innate immune defects in PIDs, with chimeric antigen receptor natural killer (CAR-NK) cells engineered for enhanced and pathogen clearance. Between 2023 and 2025, innovations in CAR-NK engineering, including IL-15 armoring and logic-gated constructs, have improved persistence and specificity, showing potential for (CGD) by targeting NADPH oxidase-deficient neutrophils; preclinical studies in CGD mouse models reported a 60% reduction in bacterial burden post-infusion. (iPSC)-derived immune cells offer an off-the-shelf alternative, differentiated into corrected T cells or macrophages for PIDs like Wiskott-Aldrich syndrome; patient-derived iPSCs edited via have generated functional NK cells with restored , paving the way for autologous therapies, including 2025 IND clearances for iPSC-based treatments in related immune disorders. Novel modalities expand treatment options beyond permanent genetic correction. Messenger RNA (mRNA) therapy provides transient enzyme replacement for PIDs with metabolic defects, such as ADA-SCID, by delivering synthetic mRNA encoding the missing protein via lipid nanoparticles; preclinical data in murine models achieved peak enzyme levels within 24 hours, sustaining immune reconstitution for weeks without genomic integration risks. Microbiome modulation targets autoinflammatory features in PIDs like common variable immunodeficiency (CVID), using fecal microbiota transplantation or defined probiotics to restore gut dysbiosis and dampen IL-6-driven inflammation; a 2024 pilot study reported normalized Th17/Treg ratios and reduced autoinflammatory flares in CVID patients post-modulation. Despite these advances, challenges persist in translating emerging therapies to clinical use. Off-target effects from , including unintended indels at similar genomic sites, pose risks of oncogenesis or immune dysregulation in PIDs, with detection assays revealing up to 5% off-target activity in HSCs; mitigation strategies like high-fidelity Cas9 variants have reduced this by 90% in recent preclinical work. Accessibility remains a barrier, as high costs (estimated at $1-2 million per treatment) and specialized manufacturing limit equitable distribution, particularly in low-resource settings. Ethically, equitable access and long-term monitoring for secondary malignancies are critical concerns. As of November 2025, ongoing IND applications and phase 1 data readouts support investigational progress for novel PID therapies, including iPSC-derived macrophages for CGD and mRNA approaches for complement deficiencies, without FDA approvals to date.

References

  1. https://iuis.org/committees/iei/
  2. https://primaryimmune.org/understanding-primary-immunodeficiency/what-is-pi
  3. https://pmc.ncbi.nlm.nih.gov/articles/PMC3245434/
  4. https://my.clevelandclinic.org/health/diseases/17964-primary-immunodeficiency
  5. https://www.cdc.gov/primary-immunodeficiency/about/index.html
  6. https://primaryimmune.org/understanding-primary-immunodeficiency/types-of-pi
  7. https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2025.1593897/full
  8. https://www.ncbi.nlm.nih.gov/books/NBK500027/
  9. https://www.uspharmacist.com/article/primary-immunodeficiency-etiology-and-incidence
  10. https://www.niaid.nih.gov/diseases-conditions/pidds-genetics-inheritance
  11. https://pmc.ncbi.nlm.nih.gov/articles/PMC6157160/
  12. https://www.niaid.nih.gov/diseases-conditions/primary-immune-deficiency-diseases-pidds
  13. https://pubmed.ncbi.nlm.nih.gov/23095909/
  14. https://pmc.ncbi.nlm.nih.gov/articles/PMC7935502/
  15. https://academic.oup.com/cei/article/118/Supplement_1/1/6461738
  16. https://link.springer.com/article/10.1007/s10875-019-00737-x
  17. https://link.springer.com/article/10.1007/s10875-022-01289-3
  18. https://pmc.ncbi.nlm.nih.gov/articles/PMC11006754/
  19. https://pmc.ncbi.nlm.nih.gov/articles/PMC5222743/
  20. https://www.cdc.gov/mmwr/pdf/rr/rr5301.pdf
  21. https://www.jacionline.org/article/s0091-6749%2809%2901162-2/fulltext
  22. https://pmc.ncbi.nlm.nih.gov/articles/PMC11464186/
  23. https://link.springer.com/article/10.1007/s10875-024-01843-1
  24. https://www.jci.org/articles/view/25178
  25. https://pmc.ncbi.nlm.nih.gov/articles/PMC4261008/
  26. https://aacijournal.biomedcentral.com/articles/10.1186/s13223-018-0317-y
  27. https://www.researchgate.net/publication/311090260_The_association_between_parental_consanguinity_and_primary_immunodeficiency_diseases_A_systematic_review_and_meta-analysis
  28. https://karger.com/iaa/article/154/1/76/166008/Parental-Consanguinity-and-the-Risk-of-Primary
  29. https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2017.00737/full
  30. https://rupress.org/jem/article/220/7/e20221105/214141/Inborn-errors-of-human-B-cell-development
  31. https://pmc.ncbi.nlm.nih.gov/articles/PMC8325549/
  32. https://www.nejm.org/doi/full/10.1056/NEJMoa1007097
  33. https://link.springer.com/article/10.1007/s10875-020-00754-1
  34. https://pmc.ncbi.nlm.nih.gov/articles/PMC8810460/
  35. https://pmc.ncbi.nlm.nih.gov/articles/PMC9178406/
  36. https://pmc.ncbi.nlm.nih.gov/articles/PMC6635466/
  37. https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2022.1023127/full
  38. https://pmc.ncbi.nlm.nih.gov/articles/PMC11714877/
  39. https://pmc.ncbi.nlm.nih.gov/articles/PMC3930833/
  40. https://www.uptodate.com/contents/malignancy-in-inborn-errors-of-immunity
  41. https://pmc.ncbi.nlm.nih.gov/articles/PMC8538991/
  42. https://www.jacionline.org/article/S0091-6749(17)30226-9/fulltext
  43. https://www.liebertpub.com/doi/10.1089/ped.2014.0453
  44. https://primaryimmune.org/understanding-primary-immunodeficiency/types-of-pi/wiskott-aldrich-syndrome-was
  45. https://respiratory-research.biomedcentral.com/articles/10.1186/s12931-019-1242-4
  46. https://pmc.ncbi.nlm.nih.gov/articles/PMC5803456/
  47. https://www.sciencedirect.com/science/article/pii/S0021755718310726
  48. https://pubmed.ncbi.nlm.nih.gov/33007500/
  49. https://primaryimmune.org/understanding-primary-immunodeficiency/types-of-pi/severe-combined-immunodeficiency-scid
  50. https://www.emjreviews.com/allergy-immunology/article/an-approach-to-diagnosing-primary-immunodeficiencies-j010125/
  51. https://rupress.org/jhi/article/1/1/e20250002/277374/The-2024-update-of-IUIS-phenotypic-classification
  52. https://info4pi.org/library/educational-materials/10-warning-signs
  53. https://pmc.ncbi.nlm.nih.gov/articles/PMC8098094/
  54. https://pmc.ncbi.nlm.nih.gov/articles/PMC9901256/
  55. https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2022.999664/full
  56. https://primaryimmune.org/resources/news-articles/all-50-states-now-screening-newborns-severe-combined-immunodeficiency-scid
  57. https://e-news.ipopi.org/portugal-spring-2025/
  58. https://www.jacionline.org/article/S0091-6749%2824%2901162-X/fulltext
  59. https://www.sciencedirect.com/science/article/abs/pii/S0929693X25001800
  60. https://www.researchgate.net/publication/377080829_Reducing_Mortality_and_Morbidity_in_Children_with_Severe_Combined_Immunodeficiency_in_Switzerland_the_Role_of_Newborn_Screening
  61. https://pmc.ncbi.nlm.nih.gov/articles/PMC3782515/
  62. https://aacijournal.biomedcentral.com/articles/10.1186/s13223-021-00617-3
  63. https://www.mdpi.com/2409-515X/7/4/72
  64. https://www.sciencedirect.com/science/article/pii/S0091674923007316
  65. https://pubmed.ncbi.nlm.nih.gov/40241596/
  66. https://link.springer.com/article/10.1007/s40274-016-2834-6
  67. https://primaryimmune.org/understanding-primary-immunodeficiency/treatment/immunoglobulin-replacement-therapy
  68. https://www.frontiersin.org/journals/pediatrics/articles/10.3389/fped.2019.00481/full
  69. https://ashpublications.org/blood/article/145/21/2408/537293/Haploidentical-HSCT-more-curative-options-for
  70. https://pubmed.ncbi.nlm.nih.gov/16112907/
  71. https://www.nejm.org/doi/full/10.1056/NEJMoa2027675
  72. https://journals.lww.com/hemasphere/fulltext/2021/01000/gene_therapy_for_primary_immunodeficiency.16.aspx
  73. https://www.ema.europa.eu/en/medicines/human/EPAR/waskyra
  74. https://www.jacionline.org/article/S0091-6749(23)01390-8/abstract
  75. https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-opportunistic-infections/pneumocystis
  76. https://www.cdc.gov/vaccines/hcp/imz-best-practices/altered-immunocompetence.html
  77. https://pmc.ncbi.nlm.nih.gov/articles/PMC4009347/
  78. https://pmc.ncbi.nlm.nih.gov/articles/PMC6939302/
  79. https://pmc.ncbi.nlm.nih.gov/articles/PMC11466791/
  80. https://primaryimmune.org/living-primary-immunodeficiency/general-care
  81. https://primaryimmune.org/sites/default/files/IDF%20Patient%20Handbook%20Chapter%2039.pdf
  82. https://pmc.ncbi.nlm.nih.gov/articles/PMC4266088/
  83. https://usidnet.org/
  84. https://igcares.com/home/education-minimize-exposure.html
  85. https://academic.oup.com/book/37211/chapter/327519283
  86. https://aacijournal.biomedcentral.com/articles/10.1186/s13223-024-00938-z
  87. https://emedicine.medscape.com/article/210249-overview
  88. https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1384195/full
  89. https://rarediseases.org/rare-diseases/common-variable-immune-deficiency/
  90. https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2017.00678/full
  91. https://link.springer.com/article/10.1007/s10875-024-01823-5
  92. https://pubmed.ncbi.nlm.nih.gov/28694805/
  93. https://journals.lww.com/co-pediatrics/fulltext/9900/sociodemographic_drivers_of_care_disparity_among.301.aspx
  94. https://www.tandfonline.com/doi/full/10.1080/1744666X.2020.1801422
  95. https://wp-iuis.s3.eu-west-1.amazonaws.com/app/uploads/2025/01/08170257/IEI-Final-Update-of-2024-Report-Jan-2025.pdf
  96. https://www.ihealthcareanalyst.com/worldwide-primary-immunodeficiency-statistics-patients-trends-market/
  97. https://pmc.ncbi.nlm.nih.gov/articles/PMC296604/
  98. https://aacijournal.biomedcentral.com/articles/10.1186/s13223-022-00662-6
  99. https://www.lidsen.com/journals/genetics/genetics-07-03-190
  100. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)00731-6/fulltext
  101. https://pmc.ncbi.nlm.nih.gov/articles/PMC7874439/
  102. https://pubmed.ncbi.nlm.nih.gov/12692709/
  103. https://www.science.org/doi/10.1126/sciimmunol.abb1662
  104. https://www.nejm.org/doi/abs/10.1056/nejm197009172831211
  105. https://onlinelibrary.wiley.com/doi/pdf/10.1080/17402520600800705
  106. https://pmc.ncbi.nlm.nih.gov/articles/PMC3342372/
  107. https://www.genenames.org/
  108. https://pubmed.ncbi.nlm.nih.gov/33409868/
  109. https://pmc.ncbi.nlm.nih.gov/articles/PMC7082388/
  110. https://pubmed.ncbi.nlm.nih.gov/36198931/
  111. https://pmc.ncbi.nlm.nih.gov/articles/PMC9857622/
  112. https://clinicaltrials.gov/study/NCT05031897
  113. https://clinicaltrials.gov/study/NCT04339777
  114. https://www.jacionline.org/article/S0091-6749(23)01208-3/fulltext
  115. https://publications.aap.org/neoreviews/article/26/9/e600/203284/Severe-Combined-Immunodeficiency-in-the-Newborn
  116. https://rupress.org/jhi/article/1/3/e20250007/278129/Inborn-errors-of-immunity-Manifestation-treatment
  117. https://link.springer.com/article/10.1007/s10875-024-01822-6
  118. https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1402038/full
  119. https://www.jacionline.org/article/S0091-6749(25)00691-8/fulltext
  120. https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2025.1661282/full
  121. https://www.nature.com/articles/s43856-025-00829-3
  122. https://www.nejm.org/doi/full/10.1056/NEJMoa2215643
  123. https://primaryimmune.org/resources/news-articles/gene-therapy-makes-headway-pi-treatment
  124. https://pmc.ncbi.nlm.nih.gov/articles/PMC7612852/
  125. https://www.frontiersin.org/journals/genome-editing/articles/10.3389/fgeed.2024.1458037/full
  126. https://pmc.ncbi.nlm.nih.gov/articles/PMC12293738/
  127. https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2025.1603757/full
  128. https://www.reprocell.com/blog/current-landscape-of-fda-stem-cell-approvals-and-trials-2023-2025
  129. https://www.sciencedirect.com/science/article/pii/S0301472X1930058X
  130. https://pmc.ncbi.nlm.nih.gov/articles/PMC9866414/
  131. https://link.springer.com/article/10.1007/s10238-023-01006-3
  132. https://pmc.ncbi.nlm.nih.gov/articles/PMC8444435/
  133. https://www.cell.com/molecular-therapy-family/nucleic-acids/fulltext/S2162-2531(25)00190-8
  134. https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2025
Add your contribution
Related Hubs
User Avatar
No comments yet.